EverGlade, a national advisory firm that helps innovators navigate the federal funding ecosystem, successfully supported Landmark Bio through negotiations to secure up to $18.3 million in funding. The ...

In this webinar, AsymBio expert Dr. Zhao will discuss robust analytical strategies for addressing these complexities, with ...

In this Drug Digest episode, Abzena’s vice president of Regulatory Strategy, Jeff Mocny, and Cellares’ director of Regulatory Affairs, Anna McMahon, examine how evolving regulatory and quality ...

Landmark Bio, an Artis BioSolutions company dedicated to accelerating the translation of next-generation advanced therapies from discovery to clinical and commercial production, today announced that ...

PFAS contamination in water is difficult to clean up and can negatively impact aquatic ecosystems. Discover how a new ...

Discover how automated protein analysis is overcoming bottlenecks in drug discovery and translational research, improving ...

NIIMBL’s 2025 National Meeting emphasized the need for system interoperability through standardization of means for data ...

With the European Medicines Agency (EMA) adopting a recommendation report to streamline the clinical procedures for biosimilars, the development ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their safety and efficacy. Method validation ensures the reliability of ...